Holen Sie sich die Stockscreener-App
0.2361
1.23%
-0.00295
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com Australia
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
PSTV: 2026 focus: CNSide scale-up, REYOBIQ pivotal trial prep, and expanded payor coverage - TradingView
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization - manilatimes.net
Plus Therapeutics plans CNS cancer test coverage for 150M US lives - Stock Titan
Plus Therapeutics, Inc. Updates Corporate Presentation on Cancer Radiotherapeutics - TradingView
Plus Therapeutics To Provide Business Update Today As Radiotherapeutic Pipeline Advances - Nasdaq
Plus Therapeutics To Provide Business Update On Thursday - TradingView
Plus Therapeutics, Inc. to Host Business Update and Conference Call on January 22, 2026 - Quiver Quantitative
Plus Therapeutics to Provide Business Update and Host - GlobeNewswire
Should you avoid Plus Therapeutics Inc stock right now2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Earnings Report: Will Plus Therapeutics Inc benefit from rising consumer demand2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Growth Value: Is Plus Therapeutics Inc a cyclical or defensive stockMarket Movement Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Aug Opening: Can Plus Therapeutics Inc reach all time highs this yearLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Prices Public Offering, Raising $15 Million - Intellectia AI
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics stock plunges after pricing $15M units offering - MSN
Plus Therapeutics (PSTV) Shares Plummet After $15M Unit Offering - GuruFocus
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
PSTV Plunges On $15 Mln Upsized Offering - Nasdaq
Plus Therapeutics (PSTV) Launches $15M Public Offering - GuruFocus
Plus Therapeutics announces pricing of upsized $15 million public offering - marketscreener.com
Plus Therapeutics Announces Pricing Of Upsized $15 Million Public Offering - TradingView — Track All Markets
CNS cancer-focused company raises $15M in stock and warrant sale - Stock Titan
Dow Update: Can Plus Therapeutics Inc reach all time highs this yearQuarterly Trade Summary & AI Enhanced Execution Alerts - baoquankhu1.vn
Sell Signal: Will Plus Therapeutics Inc stock benefit from upcoming earnings reportsJuly 2025 Recap & High Yield Stock Recommendations - moha.gov.vn
Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday - Benzinga
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - sharewise.com
How Plus Therapeutics Inc. (XMP0) stock expands through international marketsQuarterly Portfolio Review & Risk Managed Trade Strategies - ulpravda.ru
HOKA Buying Guide: Can Plus Therapeutics Inc. stock continue upward trend - ulpravda.ru
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - Sahm
Why Plus Therapeutics Inc. stock is a value investor pickStop Loss & AI Based Buy/Sell Signal Reports - ulpravda.ru
Is Plus Therapeutics Inc. stock cheap at current valuationWeekly Profit Summary & Weekly Return Optimization Plans - ulpravda.ru
0.28%
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):